Geron is a commercial-stage biopharmaceutical company developing first-in-class telomerase inhibitors to treat blood cancers, with its lead product RYTELO (imetelstat) approved for lower-risk myelodysplastic syndromes with transfusion-dependent anemia in patients ineligible for or refractory to erythropoiesis-stimulating agents. The company's telomerase inhibition approach targets malignant stem and progenitor cells by preventing telomere maintenance, thereby limiting proliferation while preserving normal cellular function, and is also being explored in clinical development for relapsed or refractory myelofibrosis and acute myeloid leukemia. Geron generates revenue primarily through direct sales of RYTELO in the United States via a commercial team focused on high-volume accounts, supported by a patient support program, while international commercialization is planned through third-party partnerships, and the company relies on patent protections and exclusivity designations to maintain competitive advantage.